Long-Term Data: While short-to-medium term studies (up to several months) indicate safety, long-term safety data (over multiple years) in broad populations is still being gathered
Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F, Huang Y, Armstrong M, Svensson M, Virnig BA, DeKosky ST, Bian J, Guo J (2024) Glucagon-like Peptide-1 receptor agonists and risk of Parkinsons Disease in patients with type 2 diabetes: a Population-based Cohort Study
On the other hand, the adverse events of GLP-1 drugs have been extensively characterized from large randomized trials with placebo controls and, in the United States, from reports derived from 12% of Americans who are currently taking these drugs
The sustained success of Jardiance underscores the strategic value of the Boehringer-Lilly partnership and the drugs expanding role in managing cardiometabolic diseases